Targeting the Human Microbiome With Antibiotics, Probiotics, and Prebiotics: Gastroenterology Enters the Metagenomics Era

Gastroenterology

Volumn 136, Issue 6, 2009, Pages 2015-2031

  Preidis, Geoffrey A ^a   Versalovic, James ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BACTERIOCIN; CEFPODOXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; FRUCTOSE OLIGOSACCHARIDE; GENTAMICIN; INULIN; KANAMYCIN; LACTULOSE; METRONIDAZOLE; NEOMYCIN; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAXIMIN; ROXITHROMYCIN; STREPTOMYCIN; SYNBIOTIC AGENT; TRINITROBENZENESULFONIC ACID; VANCOMYCIN;

ACUTE GASTROENTERITIS; ADJUVANT THERAPY; ANTIBIOTIC ASSOCIATED COLITIS; ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIBIOTIC THERAPY; ARTICLE; ATOPIC DERMATITIS; BACILLUS; BACTEROIDES; BIFIDOBACTERIUM; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; CROHN DISEASE; DIARRHEA; DIET SUPPLEMENTATION; DRUG EFFICACY; ENTERITIS; ENTEROCOCCUS; ESCHERICHIA; FECALIBACTERIUM; GASTROENTEROLOGY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; HUMAN; ILEITIS; IMMUNITY; IMMUNOSTIMULATION; INFECTION SENSITIVITY; INTESTINE FLORA; IRRITABLE COLON; LACTOBACILLUS; LACTOBACILLUS RHAMNOSUS; LACTOCOCCUS; METAGENOMICS; MICROBIAL COMMUNITY; MICROBIAL DIVERSITY; MICROBIOME; NECROTIZING ENTEROCOLITIS; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; PROPIONIBACTERIUM; SACCHAROMYCES; STREPTOCOCCUS;

EID: 65449125343     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.01.072     Document Type: Article

References (165)

1. Turnbaugh P.J., Ley R.E., Hamady M., et al. The human microbiome project. Nature 449 (2007) 804-810
2. Pennisi E. Metagenomics. Massive microbial sequence project proposed. Science 315 (2007) 1781
3. Backhed F., Ley R.E., Sonnenburg J.L., et al. Host-bacterial mutualism in the human intestine. Science 307 (2005) 1915-1920
4. Ley R.E., Peterson D.A., and Gordon J.I. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124 (2006) 837-848
5. Eckburg P.B., Bik E.M., Bernstein C.N., et al. Diversity of the human intestinal microbial flora. Science 308 (2005) 1635-1638
6. Zoetendal E.G., von Wright A., Vilpponen-Salmela T., et al. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol 68 (2002) 3401-3407
7. Zoetendal E.G., Rajilic-Stojanovic M., and de Vos W.M. High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 57 (2008) 1605-1615
8. Medini D., Serruto D., Parkhill J., et al. Microbiology in the post-genomic era. Nat Rev Microbiol 6 (2008) 419-430
9. Zaneveld J., Turnbaugh P.J., Lozupone C., et al. Host-bacterial coevolution and the search for new drug targets. Curr Opin Chem Biol 12 (2008) 109-114
10. Manichanh C., Rigottier-Gois L., Bonnaud E., et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 55 (2006) 205-211
11. Swidsinski A., Loening-Baucke V., Vaneechoutte M., et al. Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis 14 (2008) 147-161
12. Gill S.R., Pop M., Deboy R.T., et al. Metagenomic analysis of the human distal gut microbiome. Science 312 (2006) 1355-1359
13. Guarner F. Probiotics in gastrointestinal diseases. In: Versalovic J., and Wilson M. (Eds). Therapeutic microbiology: probiotics and related strategies (2008), ASM Press, Washington, DC 255-269
14. Wen L., Ley R.E., Volchkov P.Y., et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 455 (2008) 1109-1113
15. Li M., Wang B., Zhang M., et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A 105 (2008) 2117-2122
16. Kukkonen K., Savilahti E., Haahtela T., et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 119 (2007) 192-198
17. Kalliomaki M., Salminen S., Poussa T., et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 361 (2003) 1869-1871
18. Caglar E., Cildir S.K., Ergeneli S., et al. Salivary mutans streptococci and lactobacilli levels after ingestion of the probiotic bacterium Lactobacillus reuteri ATCC 55730 by straws or tablets. Acta Odontol Scand 64 (2006) 314-318
19. Anukam K., Osazuwa E., Ahonkhai I., et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect 8 (2006) 1450-1454
20. Forsythe P., and Bienenstock J. Probiotics in neurology and psychiatry. In: Versalovic J., and Wilson M. (Eds). Therapeutic microbiology: probiotics and related strategies (2008), ASM Press, Washington, DC 285-298
21. Sanders M.E. Use of probiotics and yogurts in maintenance of health. J Clin Gastroenterol 42 Suppl 2 (2008) S71-S74
22. Lomax A.R., and Calder P.C. Prebiotics, immune function, infection and inflammation: a review of the evidence. Br J Nutr (2008) 1-26
23. Jia W., Li H., Zhao L., et al. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov 7 (2008) 123-129
24. Macfarlane S., Woodmansey E.J., and Macfarlane G.T. Colonization of mucin by human intestinal bacteria and establishment of biofilm communities in a two-stage continuous culture system. Appl Environ Microbiol 71 (2005) 7483-7492
25. Hooper L.V., and Gordon J.I. Commensal host-bacterial relationships in the gut. Science 292 (2001) 1115-1118
26. Perez P.F., Dore J., Leclerc M., et al. Bacterial imprinting of the neonatal immune system: lessons from maternal cells?. Pediatrics 119 (2007) e724-e732
27. Favier C.F., de Vos W.M., and Akkermans A.D. Development of bacterial and bifidobacterial communities in feces of newborn babies. Anaerobe 9 (2003) 219-229
28. Palmer C., Bik E.M., Digiulio D.B., et al. Development of the human infant intestinal microbiota. PLoS Biol 5 (2007) e177
29. Biasucci G., Benenati B., Morelli L., et al. Cesarean delivery may affect the early biodiversity of intestinal bacteria. J Nutr 138 suppl (2008) 1796S-1800S
30. Indrio F., Riezzo G., Raimondi F., et al. The effects of probiotics on feeding tolerance, bowel habits, and gastrointestinal motility in preterm newborns. J Pediatr 152 (2008) 801-806
31. Yamanaka T., Helgeland L., Farstad I.N., et al. Microbial colonization drives lymphocyte accumulation and differentiation in the follicle-associated epithelium of Peyer's patches. J Immunol 170 (2003) 816-822
32. De La Cochetiere M.F., Durand T., Lalande V., et al. Effect of antibiotic therapy on human fecal microbiota and the relation to the development of Clostridium difficile. Microb Ecol 56 (2008) 395-402
33. Huse S.M., Dethlefsen L., Huber J.A., et al. Exploring microbial diversity and taxonomy using SSU rRNA hypervariable tag sequencing. PLoS Genet 4 (2008) e1000255
34. Dethlefsen L., Huse S., Sogin M.L., et al. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 6 (2008) e280
35. Schumann A., Nutten S., Donnicola D., et al. Neonatal antibiotic treatment alters gastrointestinal tract developmental gene expression and intestinal barrier transcriptome. Physiol Genomics 23 (2005) 235-245
36. Yap I.K., Li J.V., Saric J., et al. Metabonomic and microbiological analysis of the dynamic effect of vancomycin-induced gut microbiota modification in the mouse. J Proteome Res 7 (2008) 3718-3728
37. Bartlett J.G. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 346 (2002) 334-339
38. Sekirov I., Tam N.M., Jogova M., et al. Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection. Infect Immun 76 (2008) 4726-4736
39. Wong C.S., Jelacic S., Habeeb R.L., et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 342 (2000) 1930-1936
40. Buhling A., Radun D., Muller W.A., et al. Influence of anti-Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. Aliment Pharmacol Ther 15 (2001) 1445-1452
41. Adamsson I., Nord C.E., Lundquist P., et al. Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J Antimicrob Chemother 44 (1999) 629-640
42. Nawaz A., Mohammed I., Ahsan K., et al. Clostridium difficile colitis associated with treatment of Helicobacter pylori infection. Am J Gastroenterol 93 (1998) 1175-1176
43. Bell G.D., Powell K., Burridge S.M., et al. Experience with "triple" anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 6 (1992) 427-435
44. Tong J.L., Ran Z.H., Shen J., et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 25 (2007) 155-168
45. Cotter P.D., Hill C., and Ross R.P. Bacteriocins: developing innate immunity for food. Nat Rev Microbiol 3 (2005) 777-788
46. Spinler J.K., Taweechotipatr M., Rognerud C.L., et al. Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe 14 (2008) 166-171
47. Medellin-Pena M.J., Wang H., Johnson R., et al. Probiotics affect virulence-related gene expression in Escherichia coli O157:H7. Appl Environ Microbiol 73 (2007) 4259-4267
48. Jelcic I., Hufner E., Schmidt H., et al. Repression of the locus of the enterocyte effacement-encoded regulator of gene transcription of Escherichia coli O157:H7 by Lactobacillus reuteri culture supernatants is LuxS and strain dependent. Appl Environ Microbiol 74 (2008) 3310-3314
49. Corr S.C., Li Y., Riedel C.U., et al. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci U S A 104 (2007) 7617-7621
50. Metchnikoff E. The prolongation of life: optimistic studies (2004), Springer Publishing Company, Inc, New York, NY
51. Fuller R. Probiotics in man and animals. J Appl Bacteriol 66 (1989) 365-378
52. FAO/WHO. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria (2001), World Health Organization, Basel, Switzerland
53. Walker R., and Buckley M. Probiotic microbes: the scientific basis (2006), American Academy of Microbiology, Washington, DC
54. Barc M.C., Charrin-Sarnel C., Rochet V., et al. Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: influence of Saccharomyces boulardii. Anaerobe 14 (2008) 229-233
55. Haller D., Bode C., Hammes W.P., et al. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut 47 (2000) 79-87
56. Fujii T., Ohtsuka Y., Lee T., et al. Bifidobacterium breve enhances transforming growth factor beta1 signaling by regulating Smad7 expression in preterm infants. J Pediatr Gastroenterol Nutr 43 (2006) 83-88
57. Hart A.L., Lammers K., Brigidi P., et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 53 (2004) 1602-1609
58. von der Weid T., Bulliard C., and Schiffrin E.J. Induction by a lactic acid bacterium of a population of CD4(+) T cells with low proliferative capacity that produce transforming growth factor beta and interleukin-10. Clin Diagn Lab Immunol 8 (2001) 695-701
59. Baba N., Samson S., Bourdet-Sicard R., et al. Commensal bacteria trigger a full dendritic cell maturation program that promotes the expansion of non-Tr1 suppressor T cells. J Leukoc Biol 84 (2008) 468-476
60. Neish A.S., Gewirtz A.T., Zeng H., et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 289 (2000) 1560-1563
61. Kelly D., Campbell J.I., King T.P., et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 5 (2004) 104-112
62. Lin Y.P., Thibodeaux C.H., Pena J.A., et al. Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis 14 (2008) 1068-1083
63. Iyer C., Kosters A., Sethi G., et al. Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kappaB and MAPK signalling. Cell Microbiol 10 (2008) 1442-1452
64. Christensen H.R., Frokiaer H., and Pestka J.J. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol 168 (2002) 171-178
65. Otte J.M., and Podolsky D.K. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 286 (2004) G613-G626
66. Ruiz P.A., Hoffmann M., Szcesny S., et al. Innate mechanisms for Bifidobacterium lactis to activate transient pro-inflammatory host responses in intestinal epithelial cells after the colonization of germ-free rats. Immunology 115 (2005) 441-450
67. Holtta V., Klemetti P., Sipponen T., et al. IL-23/IL-17 immunity as a hallmark of Crohn's disease. Inflamm Bowel Dis 14 (2008) 1175-1184
68. Atarashi K., Nishimura J., Shima T., et al. ATP drives lamina propria T(H)17 cell differentiation. Nature 455 (2008) 808-812
69. Zaph C., Du Y., Saenz S.A., et al. Commensal-dependent expression of IL-25 regulates the IL-23-IL-17 axis in the intestine. J Exp Med 205 (2008) 2191-2198
70. Mazmanian S.K., Round J.L., and Kasper D.L. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453 (2008) 620-625
71. Smits H.H., van Beelen A.J., Hessle C., et al. Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development. Eur J Immunol 34 (2004) 1371-1380
72. So J.S., Lee C.G., Kwon H.K., et al. Lactobacillus casei potentiates induction of oral tolerance in experimental arthritis. Mol Immunol 46 (2008) 172-180
73. Delcenserie V., Martel D., Lamoureux M., et al. Immunomodulatory effects of probiotics in the intestinal tract. Curr Issues Mol Biol 10 (2008) 37-54
74. He B., Xu W., Santini P.A., et al. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 26 (2007) 812-826
75. Peterson D.A., McNulty N.P., Guruge J.L., et al. IgA response to symbiotic bacteria as a mediator of gut homeostasis. Cell Host Microbe 2 (2007) 328-339
76. Seth A., Yan F., Polk D.B., et al. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism. Am J Physiol Gastrointest Liver Physiol 294 (2008) G1060-G1069
77. Johnson-Henry K.C., Donato K.A., Shen-Tu G., et al. Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function. Infect Immun 76 (2008) 1340-1348
78. Borthakur A., Gill R.K., Tyagi S., et al. The probiotic Lactobacillus acidophilus stimulates chloride/hydroxyl exchange activity in human intestinal epithelial cells. J Nutr 138 (2008) 1355-1359
79. Fujiya M., Musch M.W., Nakagawa Y., et al. The Bacillus subtilis quorum-sensing molecule CSF contributes to intestinal homeostasis via OCTN2, a host cell membrane transporter. Cell Host Microbe 1 (2007) 299-308
80. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118 (2004) 229-241
81. Gibson G.R., and Roberfroid M.B. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 125 (1995) 1401-1412
82. Gibson G.R. Prebiotics as gut microflora management tools. J Clin Gastroenterol 42 Suppl 2 (2008) S75-S79
83. Rowland I. Prebiotics in human medicine. In: Versalovic J., and Wilson M. (Eds). Therapeutic microbiology: probiotics and related strategies (2008), ASM Press, Washington DC 299-306
84. Sakata T. Stimulatory effect of short-chain fatty acids on epithelial cell proliferation in the rat intestine: a possible explanation for trophic effects of fermentable fibre, gut microbes and luminal trophic factors. Br J Nutr 58 (1987) 95-103
85. Saulnier D.M., Gibson G.R., and Kolida S. In vitro effects of selected synbiotics on the human faecal microbiota composition. FEMS Microbiol Ecol 66 (2008) 516-527
86. Panigrahi P., Parida S., Pradhan L., et al. Long-term colonization of a Lactobacillus plantarum synbiotic preparation in the neonatal gut. J Pediatr Gastroenterol Nutr 47 (2008) 45-53
87. Kukkonen K., Savilahti E., Haahtela T., et al. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics 122 (2008) 8-12
88. Taylor D.N., Bourgeois A.L., Ericsson C.D., et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg 74 (2006) 1060-1066
89. Shornikova A.V., Casas I.A., Isolauri E., et al. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr 24 (1997) 399-404
90. Sarker S.A., Sultana S., Fuchs G.J., et al. Lactobacillus paracasei strain ST11 has no effect on rotavirus but ameliorates the outcome of nonrotavirus diarrhea in children from Bangladesh. Pediatrics 116 (2005) e221-e228
91. Canani R.B., Cirillo P., Terrin G., et al. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 335 (2007) 340
92. Allen S.J., Okoko B., Martinez E., et al. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev (2004) CD003048
93. Huang J.S., Bousvaros A., Lee J.W., et al. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci 47 (2002) 2625-2634
94. Bengmark S. Synbiotics in human medicine. In: Versalovic J., and Wilson M. (Eds). Therapeutic microbiology: probiotics and related strategies (2008), ASM Press, Washington, DC 307-321
95. Binns C.W., Lee A.H., Harding H., et al. The CUPDAY Study: prebiotic-probiotic milk product in 1-3-year-old children attending childcare centres. Acta Paediatr 96 (2007) 1646-1650
96. Pillai A., and Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev (2008) CD004611
97. Johnston B.C., Supina A.L., Ospina M., et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev (2007) CD004827
98. Segarra-Newnham M. Probiotics for Clostridium difficile-associated diarrhea: focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii. Ann Pharmacother 41 (2007) 1212-1221
99. Hickson M., D'Souza A.L., Muthu N., et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 335 (2007) 80
100. D'Souza A.L., Rajkumar C., Cooke J., et al. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 324 (2002) 1361
101. Lewis S., Burmeister S., and Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol 3 (2005) 442-448
102. Orrhage K., Sjostedt S., and Nord C.E. Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil. J Antimicrob Chemother 46 (2000) 603-612
103. Sartor R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology 134 (2008) 577-594
104. Pena J.A., Rogers A.B., Ge Z., et al. Probiotic Lactobacillus spp. diminish Helicobacter hepaticus-induced inflammatory bowel disease in interleukin-10-deficient mice. Infect Immun 73 (2005) 912-920
105. McCarthy J., O'Mahony L., O'Callaghan L., et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 52 (2003) 975-980
106. Madsen K.L., Doyle J.S., Jewell L.D., et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 116 (1999) 1107-1114
107. Schultz M., Veltkamp C., Dieleman L.A., et al. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis 8 (2002) 71-80
108. Isaacs K., and Herfarth H. Role of probiotic therapy in IBD. Inflamm Bowel Dis 14 (2008) 1597-1605
109. Bibiloni R., Fedorak R.N., Tannock G.W., et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100 (2005) 1539-1546
110. Gionchetti P., Rizzello F., Helwig U., et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124 (2003) 1202-1209
111. Mimura T., Rizzello F., Helwig U., et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53 (2004) 108-114
112. Fitzpatrick L.R., Hertzog K.L., Quatse A.L., et al. Effects of the probiotic formulation VSL#3 on colitis in weanling rats. J Pediatr Gastroenterol Nutr 44 (2007) 561-570
113. Feighery L.M., Smith P., O'Mahony L., et al. Effects of Lactobacillus salivarius 433118 on intestinal inflammation, immunity status and in vitro colon function in two mouse models of inflammatory bowel disease. Dig Dis Sci 53 (2008) 2495-2506
114. Welters C.F., Heineman E., Thunnissen F.B., et al. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum 45 (2002) 621-627
115. Lindsay J.O., Whelan K., Stagg A.J., et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 55 (2006) 348-355
116. Macfarlane S., Macfarlane G.T., and Cummings J.H. Review article: prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther 24 (2006) 701-714
117. Geier M.S., Butler R.N., Giffard P.M., et al. Prebiotic and synbiotic fructooligosaccharide administration fails to reduce the severity of experimental colitis in rats. Dis Colon Rectum 50 (2007) 1061-1069
118. Furrie E., Macfarlane S., Kennedy A., et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54 (2005) 242-249
119. Chermesh I., Tamir A., Reshef R., et al. Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Dig Dis Sci 52 (2007) 385-389
120. Sokol H., Pigneur B., Watterlot L., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105 (2008) 16730-16736
121. Isaacs K.L., and Sartor R.B. Treatment of inflammatory bowel disease with antibiotics. Gastroenterol Clin North Am 33 (2004) 335-345 x
122. Shen B., Achkar J.P., Lashner B.A., et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 7 (2001) 301-305
123. Prantera C., Lochs H., Campieri M., et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 23 (2006) 1117-1125
124. Selby W., Pavli P., Crotty B., et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 132 (2007) 2313-2319
125. Kuenstner J.T. The Australian antibiotic trial in Crohn's disease: alternative conclusions from the same study[letter]. Gastroenterology 133 (2007) 1742-1743 author reply 1745-1746
126. Kang S.S., Bloom S.M., Norian L.A., et al. An antibiotic-responsive mouse model of fulminant ulcerative colitis. PLoS Med 5 (2008) e41
127. Tamagawa H., Hiroi T., Mizushima T., et al. Therapeutic effects of roxithromycin in interleukin-10-deficient colitis. Inflamm Bowel Dis 13 (2007) 547-556
128. Nikfar S., Rahimi R., Rahimi F., et al. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 51 (2008) 1775-1780
129. McFarland L.V., and Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 14 (2008) 2650-2661
130. O'Mahony L., McCarthy J., Kelly P., et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128 (2005) 541-551
131. Williams E., Stimpson J., Wang D., et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study [published online ahead of print September 9, 2008]. Aliment Pharmacol Ther 29 (2009) 97-103
132. Savino F., Pelle E., Palumeri E., et al. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics 119 (2007) e124-e1230
133. Verdu E.F., Bercik P., Verma-Gandhu M., et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 55 (2006) 182-190
134. Rousseaux C., Thuru X., Gelot A., et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 13 (2007) 35-37
135. Hunter J.O., Tuffnell Q., and Lee A.J. Controlled trial of oligofructose in the management of irritable bowel syndrome. J Nutr 12 suppl (1999) 1451S-1453S
136. Mihatsch W.A., Hoegel J., and Pohlandt F. Prebiotic oligosaccharides reduce stool viscosity and accelerate gastrointestinal transport in preterm infants. Acta Paediatr 95 (2006) 843-848
137. Andriulli A., Neri M., Loguercio C., et al. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study. J Clin Gastroenterol 42 Suppl 3 Pt 2 (2008) S218-S223
138. Pimentel M., Chow E.J., and Lin H.C. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95 (2000) 3503-3506
139. Pimentel M., Chow E.J., and Lin H.C. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98 (2003) 412-419
140. Sharara A.I., Aoun E., Abdul-Baki H., et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101 (2006) 326-333
141. Pimentel M., Park S., Mirocha J., et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 145 (2006) 557-563
142. Frissora C.L., and Cash B.D. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther 25 (2007) 1271-1281
143. Maxwell P.R., Rink E., Kumar D., et al. Antibiotics increase functional abdominal symptoms. Am J Gastroenterol 97 (2002) 104-108
144. Brook I. Microbiology and management of neonatal necrotizing enterocolitis. Am J Perinatol 25 (2008) 111-118
145. Bury R.G., and Tudehope D. Enteral antibiotics for preventing necrotizing enterocolitis in low birthweight or preterm infants. Cochrane Database Syst Rev (2001) CD000405
146. Krediet T.G., van Lelyveld N., Vijlbrief D.C., et al. Microbiological factors associated with neonatal necrotizing enterocolitis: protective effect of early antibiotic treatment. Acta Paediatr 92 (2003) 1180-1182
147. Alfaleh K., and Bassler D. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev (2008) CD005496
148. Deshpande G., Rao S., and Patole S. Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: a systematic review of randomised controlled trials. Lancet 369 (2007) 1614-1620
149. Bin-Nun A., Bromiker R., Wilschanski M., et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr 147 (2005) 192-196
150. Siggers R.H., Siggers J., Boye M., et al. Early administration of probiotics alters bacterial colonization and limits diet-induced gut dysfunction and severity of necrotizing enterocolitis in preterm pigs. J Nutr 138 (2008) 1437-1444
151. De Plaen I.G., Liu S.X., Tian R., et al. Inhibition of nuclear factor-kappaB ameliorates bowel injury and prolongs survival in a neonatal rat model of necrotizing enterocolitis. Pediatr Res 61 (2007) 716-721
152. Stappenbeck T.S., Hooper L.V., and Gordon J.I. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci U S A 99 (2002) 15451-15455
153. Lin P.W., and Stoll B.J. Necrotising enterocolitis. Lancet 368 (2006) 1271-1283
154. Versalovic J.W.M. Therapeutic microbiology: probiotics and related strategies (2008), ASM Press, Washington, DC
155. McGuire A.L., Colgrove J., Whitney S.N., et al. Ethical, legal, and social considerations in conducting the Human Microbiome Project. Genome Res 18 (2008) 1861-1864
156. Braga-Neto M.B., Warren C.A., Oria R.B., et al. Alanyl-glutamine and glutamine supplementation improves 5-fluorouracil-induced intestinal epithelium damage in vitro. Dig Dis Sci 53 (2008) 2687-2696
157. Becker R.M., Wu G., Galanko J.A., et al. Reduced serum amino acid concentrations in infants with necrotizing enterocolitis. J Pediatr 137 (2000) 785-793
158. Louis P., Scott K.P., Duncan S.H., et al. Understanding the effects of diet on bacterial metabolism in the large intestine. J Appl Microbiol 102 (2007) 1197-1208
159. Duncan S.H., Hold G.L., Barcenilla A., et al. Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces. Int J Syst Evol Microbiol 52 (2002) 1615-1620
160. Focareta A., Paton J.C., Morona R., et al. A recombinant probiotic for treatment and prevention of cholera. Gastroenterology 130 (2006) 1688-1695
161. Carroll I.M., Andrus J.M., Bruno-Barcena J.M., et al. Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis. Am J Physiol Gastrointest Liver Physiol 293 (2007) G729-G738
162. Braat H., Rottiers P., Hommes D.W., et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 4 (2006) 754-759
163. Turnbaugh P.J., Ley R.E., Mahowald M.A., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444 (2006) 1027-1031
164. Guerrant R.L., Oria R.B., Moore S.R., et al. Malnutrition as an enteric infectious disease with long-term effects on child development. Nutr Rev 66 (2008) 487-505
165. Petri Jr. W.A., Miller M., Binder H.J., et al. Enteric infections, diarrhea, and their impact on function and development. J Clin Invest 118 (2008) 1277-1290